Natixis Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.23M Buy
100,399
+28,747
+40% +$687K ﹤0.01% 1080
2025
Q4
$1.91M Buy
71,652
+7,418
+12% +$177K ﹤0.01% 1062
2025
Q3
$1.37M Sell
64,234
-7,944
-11% -$188K ﹤0.01% 1218
2025
Q2
$1.56M Buy
72,178
+9,283
+15% +$173K ﹤0.01% 1166
2025
Q1
$1.04M Buy
62,895
+15,888
+34% +$289K ﹤0.01% 1262
2024
Q4
$863K Buy
47,007
+6,519
+16% +$105K ﹤0.01% 1347
2024
Q3
$623K Buy
40,488
+14,961
+59% +$250K ﹤0.01% 1414
2024
Q2
$415K Buy
25,527
+7,697
+43% +$124K ﹤0.01% 1471
2024
Q1
$330K Sell
17,830
-23,045
-56% -$571K ﹤0.01% 1464
2023
Q4
$1.28M Buy
40,875
+6,112
+18% +$146K ﹤0.01% 1138
2023
Q3
$724K Buy
34,763
+9,676
+39% +$263K ﹤0.01% 1257
2023
Q2
$601K Buy
25,087
+11,110
+79% +$247K ﹤0.01% 1293
2023
Q1
$263K Buy
+13,977
New +$266K ﹤0.01% 1425

Other funds holding ACAD